About: Betibeglogene autotemcel

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Betibeglogene autotemcel, sold under the brand name Zynteglo, is a medication for the treatment for beta thalassemia. It was developed by Bluebird Bio and was given breakthrough therapy designation by the U.S. Food and Drug Administration in February 2015. It was approved for medical use in the European Union in May 2019, and in the United States in August 2022.

Property Value
dbo:abstract
  • Betibeglogene autotemcel, sold under the brand name Zynteglo, is a medication for the treatment for beta thalassemia. It was developed by Bluebird Bio and was given breakthrough therapy designation by the U.S. Food and Drug Administration in February 2015. The most common adverse reactions include reduced platelet and other blood cell levels, as well as mucositis, febrile neutropenia, vomiting, pyrexia (fever), alopecia (hair loss), epistaxis (nosebleed), abdominal pain, musculoskeletal pain, cough, headache, diarrhea, rash, constipation, nausea, decreased appetite, pigmentation disorder and pruritus (itch). It was approved for medical use in the European Union in May 2019, and in the United States in August 2022. (en)
  • LentiGlobin BB305是一種治療的實驗性療法，β-地中海貧血是一種罕見但可能會使人衰弱的血液疾病。這項療法由開發，並在2015年2月獲美国食品药品监督管理局指定為「突破性療法」。在早期的臨床試驗中，數位需要長期輸血治療的患者在此療法後能夠更長時間不用輸血。 (zh)
dbo:alternativeName
  • Zynteglo (en)
dbo:fdaUniiCode
  • MEE8487RTP
dbo:kegg
  • D11930
dbo:wikiPageID
  • 45389775 (xsd:integer)
dbo:wikiPageLength
  • 19131 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1122713907 (xsd:integer)
dbo:wikiPageWikiLink
dbp:atcPrefix
  • B06 (en)
dbp:atcSuffix
  • AX02 (en)
dbp:dailymedid
  • Betibeglogene autotemcel (en)
dbp:kegg
  • D11930 (en)
dbp:legalEu
  • Rx-only (en)
dbp:legalStatus
  • Rx-only (en)
dbp:legalUk
  • POM (en)
dbp:legalUs
  • Rx-only (en)
dbp:licenceEu
  • yes (en)
dbp:pregnancyCategory
dbp:routesOfAdministration
dbp:synonyms
  • LentiGlobin BB305, autologous CD34+ cells encoding βA-T87Q-globin gene (en)
dbp:tradename
  • Zynteglo (en)
dbp:unii
  • MEE8487RTP (en)
dbp:wikiPageUsesTemplate
dcterms:subject
rdf:type
rdfs:comment
  • LentiGlobin BB305是一種治療的實驗性療法，β-地中海貧血是一種罕見但可能會使人衰弱的血液疾病。這項療法由開發，並在2015年2月獲美国食品药品监督管理局指定為「突破性療法」。在早期的臨床試驗中，數位需要長期輸血治療的患者在此療法後能夠更長時間不用輸血。 (zh)
  • Betibeglogene autotemcel, sold under the brand name Zynteglo, is a medication for the treatment for beta thalassemia. It was developed by Bluebird Bio and was given breakthrough therapy designation by the U.S. Food and Drug Administration in February 2015. It was approved for medical use in the European Union in May 2019, and in the United States in August 2022. (en)
rdfs:label
  • Betibeglogene autotemcel (en)
  • LentiGlobin BB305 (zh)
owl:sameAs
prov:wasDerivedFrom
foaf:isPrimaryTopicOf
is dbo:product of
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is dbp:products of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License